Skip to main content

Table 3 Net clinical benefits for each treatment according to different weight models

From: The optimal antithrombotic strategy for post-stroke patients with atrial fibrillation and extracranial artery stenosis—a nationwide cohort study

Stroke prevention strategy

NCB based on different weight models, % per year (95% CI)

Relative weight of ICH compared to ischemic stroke according to Singer et al.[20] Weight = 1.5

Relative weight of ICH compared to ischemic stroke according to Connolly et al.[21]  Weight = 3.08

Relative weight of ICH compared to ischemic stroke according to Lip et al.[22]  Weight = 2.44

Compared to AP (Reference group)

 NOACs

3.65 (3.32 to 3.98)

3.84 (3.63 to 4.05)

3.76 (3.45 to 4.07)

 Warfarin

-2.13 (-2.28 to -1.98)

-2.46 (-2.56 to -2.36)

-2.32 (-2.45 to -2.19)

 AP + NOACs

-2.87 (-3.00 to -2.74)

-2.81 (-2.90 to -2.72)

-2.83 (-2.94 to -2.72)

 AP + Warfarin

-1.80 (-1.95 to -1.64)

-2.28 (-2.39 to -2.18)

-2.09 (-2.22 to -1.95)

  1. AP Anti-platelet agents, CI Confidence interval, ICH Intra-cranial hemorrhage, NCB Net clinical benefit, NOACs Non–vitamin K antagonist oral anticoagulants